Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling

Measuring the biological effect of presurgical metformin treatment in endometrial cancer

(2016) V N Sivalingam et al.   BRITISH JOURNAL OF CANCER

Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway

(2016) Jingfang Zou et al.   CANCER SCIENCE

The prognostic role of metformin in patients with endometrial cancer: a retrospective study

(2016) Veronika Seebacher et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer

(2016) Dongge Cai et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation

(2016) Caihong Bai et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Different effects of prenatal stress on ERK2/CREB/Bcl-2 expression in the hippocampus and the prefrontal cortex of adult offspring rats

(2016) Zeen Zhu et al.   NEUROREPORT

Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology

(2016) Thomas Hart et al.   Scientific Reports

Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models

(2015) Stefanie Schrauwen et al.   GYNECOLOGIC ONCOLOGY

Targeting PI3 kinase in cancer

(2015) Todd M. Bauer et al.   PHARMACOLOGY & THERAPEUTICS

Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells

(2015) Jinkyoung Kim et al.   TUMOR BIOLOGY

The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer

(2015) Leszek Gottwald et al.   Ginekologia Polska

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

(2014) HaiXia Li et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

β-lapachone-Induced Apoptosis of Human Gastric Carcinoma AGS Cells Is Caspase-Dependent and Regulated by the PI3K/Akt Pathway

(2014) Hai Yang Yu et al.   Biomolecules & Therapeutics

Endometrial cancer: A review and current management strategies: Part I

(2014) William M. Burke et al.   GYNECOLOGIC ONCOLOGY

mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review

(2014) Nader Husseinzadeh et al.   GYNECOLOGIC ONCOLOGY

Deguelin Inhibits the Migration and Invasion of U-2 OS Human Osteosarcoma Cells via the Inhibition of Matrix Metalloproteinase-2/-9 in Vitro

(2014) Hung-Sheng Shang et al.   MOLECULES

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

(2014) Kevin M. Schuler et al.   Cancer Medicine

Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects

(2012) Arian Emami Riedmaier et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Expression of ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma

(2011) K. Kosmas et al.   DIAGNOSTIC CYTOPATHOLOGY

Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway

(2010) S Murayama-Hosokawa et al.   ONCOGENE

Is it Time to Test Metformin in Breast Cancer Clinical Trials?

(2009) M. Cazzaniga et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Current status of gynecologic cancer in Japan

(2009) Kimio Ushijima   Journal of Gynecologic Oncology